Once we publish, maybe we'll start getting some gr

Quote:

---

Once we publish, maybe we'll start getting some grants like this.

---

Their drug bezisterim selectively inhibited pro-inflammatory ERK/NK-kB signaling. All of which are on the leronlimab regulator list and downregulated. You have to wonder how drug companies catch the eye of the DoD, NIH or other federal agencies.